Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202400908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Fei Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, P. R. China. Hauptthemen laut MEDLINE: Lung Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Chemoradiotherapy, Benzimidazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Projects, NUS School of Medicine Dean's Office with reference Nos..
Abstract (Originalsprache)
The implementation of chemoradiation combinations has gained great momentum in clinical practices. However, the full utility of this paradigm is often restricted by the discordant tempos of action of chemotherapy and radiotherapy. Here, a gold nanoparticle‐based radiation‐responsive nanovesicle system loaded with cisplatin and veliparib, denoted as CV‐Au NVs, is developed to augment the concurrent chemoradiation effect in a spatiotemporally controllable manner of drug release. Upon irradiation, the in situ generation of •OH induces the oxidation of polyphenylene sulfide from being hydrophobic to hydrophilic, resulting in the disintegration of the nanovesicles and the rapid release of the entrapped cisplatin and veliparib (the poly ADP‐ribose polymerase (PARP) inhibitor). Cisplatin‐induced DNA damage and the impairment of the DNA repair mechanism mediated by veliparib synergistically elicit potent pro‐apoptotic effects. In vivo studies suggest that one‐dose injection of the CV‐Au NVs and one‐time X‐ray irradiation paradigm effectively inhibit tumor growth in the A549 lung cancer model. This study provides new insight into designing nanomedicine platforms in chemoradiation therapy from a vantage point of synergizing both chemotherapy and radiation therapy in a spatiotemporally concurrent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, P. R. China.
- State Key Laboratory of Vaccines for Infectious Diseases Center for Molecular Imaging and Translational Medicine, Xiang'An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, 361102, P. R. China.
- Departments of Diagnostic Radiology, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore,…
- Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore.
- Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
- Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore, 138673, Singapore.
ORCID-Profile: Xiaoyuan Chen
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Projects
- NUS School of Medicine Dean's Office with reference Nos.
- National Medical Research Council
- Singapore Ministry of Education
- National Research Foundation
Zitieren
APA
Kang, F., Niu, M., Zhou, Z., Zhang, M., Xiong, H., Zeng, F., Wang, J., & Chen, X. (2024). Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400908
Vancouver
Kang F, Niu M, Zhou Z, Zhang M, Xiong H, Zeng F, et al. Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400908
BibTeX
@article{Kang2024,
author = {Kang, Fei and Niu, Meng and Zhou, Zijian and Zhang, Mingru and Xiong, Hehe and Zeng, Fantian and Wang, Jing and Chen, Xiaoyuan},
title = {Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202400908}
}
EUVIMED